2017 Fiscal Year Final Research Report
Role of tumor-derived semaphorin 3A in the development of cancer pain
| Project/Area Number |
15K08682
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pain science
|
|---|
| Research Institution | Nigata University of Phermacy and Applied Life Sciences |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山田 大祐 新潟薬科大学, 薬学部, 助手 (50733680)
川原 浩一 新潟薬科大学, 薬学部, 准教授 (10347015)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | セマフォリン3A / がん性疼痛 / mTOR / がん幹細胞 / 薬剤抵抗性 |
|---|
| Outline of Final Research Achievements |
Elucidation of potential therapeutic targets for bone cancer pain would contribute to relief of the intractable and unbearable pain. We used microarray analysis to reveal upregulation of semaphorin 3A (Sema3A) in the model mice for bone cancer pain. Knockdown of Sema3A and inhibition of Sema3A cellular signaling attenuated the tumor growth and the development of the pain. These results suggest that Sema3A is a potential therapeutic target molecule for the development of bone cancer pain.
|
| Free Research Field |
薬理学
|
